High-throughput screening for broad-spectrum chemical inhibitors of RNA viruses

Journal of Visualized Experiments

Volumn , Issue 87, 2014, Pages

  Lucas Hourani, Marianne ^a   Munier Lehmann, Hélène ^a   Helynck, Olivier ^a   Komarova, Anastassia ^a   Desprès, Philippe ^a   Tangy, Frédéric ^a   Vidalain, Pierre Olivier ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Broad spectrum antivirals; Chemical libraries; Chikungunya virus; High throughput screening assays; Immunology; Issue 87; Luciferase reporter; Measles virus; Viral infections

Indexed keywords

EID: 84922661326     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51222     Document Type: Article

References (35)

1. De Clercq, E. Antiviral drugs in current clinical use. J Clin Virol. 30, 115-133, doi:10.1016/j.jcv.2004.02.009 (2004).
2. Debing, Y., Jochmans, D., & Neyts, J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol. doi:S1879-6257(13)00025-4 [pii] 10.1016/j.coviro.2013.03.001 (2013).
3. Leyssen, P., De Clercq, E., & Neyts, J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 78, 9-25, doi:10.1016/j.antiviral.2008.01.004 S0166-3542(08)00024-7 [pii] (2008).
4. Leyssen, P., Balzarini, J., De Clercq, E., & Neyts, J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol. 79, 1943-1947, doi:79/3/1943 [pii] 10.1128/JVI.79.3.1943-1947.2005 (2005).
5. Wang, B. X., & Fish, E. N. The yin and yang of viruses and interferons. Trends Immunol. 33, 190-197, doi:10.1016/j.it.2012.01.004 S1471-4906(12)00005-1 [pii] (2012).
6. Empey, K. M., Peebles, R. S., Jr., & Kolls, J. K. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis. 50, 1258-1267, doi:10.1086/651603 (2010).
7. Tan, S. L., Ganji, G., Paeper, B., Proll, S., & Katze, M. G. Systems biology and the host response to viral infection. Nat Biotechnol. 25, 1383-1389, doi:nbt1207-1383 [pii] 10.1038/nbt1207-1383 (2007).
8. Prussia, A., Thepchatri, P., Snyder, J. P., & Plemper, R. K. Systematic Approaches towards the Development of Host-Directed Antiviral Therapeutics. Int J Mol Sci. 12, 4027-4052, doi:10.3390/ijms12064027 ijms-12-04027 [pii] (2011).
9. Connolly, D. J., & O'Neill, L. A. New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol. doi:S1471-4892(12)00100-2 [pii] 10.1016/j.coph.2012.06.002 (2012).
10. Thakur, C. S., et al. Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proc Natl Acad Sci U S A. 104, 9585-9590, doi:0700590104 [pii] 10.1073/pnas.0700590104 (2007).
11. Shoji-Kawata, S., et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature. 494, 201-206, doi:10.1038/nature11866 nature11866 [pii] (2013).
12. Hoffman, E. S., Smith, R. E., & Renaud, R. C., Jr. From the analyst's couch: TLR-targeted therapeutics. Nat Rev Drug Discov. 4, 879-880 (2005).
13. Bonavia, A., et al. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci U S A. 108, 6739-6744, doi:1017142108 [pii] 10.1073/pnas.1017142108 (2011).
14. Rider, T. H., et al. Broad-spectrum antiviral therapeutics. PLoS One. 6, e22572, doi:10.1371/journal.pone.0022572 PONE-D-11-08992 [pii] (2011).
15. Krumm, S. A., et al. Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS One. 6, e20069, doi:10.1371/journal.pone.0020069 PONE-D-11-01284 [pii] (2011).
16. Hoffmann, H. H., Kunz, A., Simon, V. A., Palese, P., & Shaw, M. L. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A. 108, 5777-5782, doi:1101143108 [pii] 10.1073/pnas.1101143108 (2011).
17. Harvey, R., et al. GSK983: a novel compound with broad-spectrum antiviral activity. Antiviral Res. 82, 1-11, doi:10.1016/j.antiviral.2008.12.015 S0166-3542(09)00016-3 [pii] (2009).
18. Swinney, D. C., & Anthony, J. How were new medicines discovered? Nat Rev Drug Discov. 10, 507-519, doi:10.1038/nrd3480 nrd3480 [pii] (2011).
19. Jochmans, D., Leyssen, P., & Neyts, J. A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE. J Virol Methods. 183, 176-179, doi:10.1016/j.jviromet.2012.04.011 S0166-0934(12)00138-3 [pii] (2012).
20. Puig-Basagoiti, F., et al. High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob Agents Chemother. 49, 4980-4988, doi:49/12/4980 [pii] 10.1128/AAC.49.12.4980-4988.2005 (2005).
21. Panchal, R. G., et al. Development of high-content imaging assays for lethal viral pathogens. J Biomol Screen. 15, 755-765, doi:10.1177/1087057110374357 1087057110374357 [pii] (2010).
22. Pohjala, L., et al. Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS One. 6, e28923, doi:10.1371/journal.pone.0028923 PONE-D-11-11200 [pii] (2011).
23. Zou, G., Xu, H. Y., Qing, M., Wang, Q. Y., & Shi, P. Y. Development and characterization of a stable luciferase dengue virus for high-throughput screening. Antiviral Res. 91, 11-19, doi:10.1016/j.antiviral.2011.05.001 S0166-3542(11)00297-X [pii] (2011).
24. Thorne, N., Inglese, J., & Auld, D. S. Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem Biol. 17, 646-657, doi:10.1016/j.chembiol.2010.05.012 S1074-5521(10)00197-3 [pii] (2010).
25. Komarova, A. V., et al. Proteomic analysis of virus-host interactions in an infectious context using recombinant viruses. Mol Cell Proteomics. 10, M110 007443, doi:10.1074/mcp.M110.007443 M110.007443 [pii] (2011).
26. Henrik Gad, H., et al. The E2-E166K substitution restores Chikungunya virus growth in OAS3 expressing cells by acting on viral entry. Virology. 434, 27-37, doi:10.1016/j.virol.2012.07.019 S0042-6822(12)00368-6 [pii] (2012).
27. Wang, Q. Y., et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol.85, 6548-6556, doi:JVI.02510-10 [pii] 10.1128/JVI.02510-10 (2011).
28. Smee, D. F., Hurst, B. L., & Day, C. W. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother. 22, 263-272, doi:10.3851/IMP2105 (2012).
29. Zhang, J. H., Chung, T. D., & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 4, 67-73 (1999).
30. Qing, M., et al. Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob Agents Chemother. 54, 3686-3695, doi:10.1128/AAC.00561-10 AAC.00561-10 [pii] (2010).
31. Munier-Lehmann, H., Vidalain, P. O., Tangy, F., & Janin, Y. L. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 56, 3148-3167, doi:10.1021/jm301848w (2013).
32. Yoon, J. J., et al. High-throughput screening-based identification of paramyxovirus inhibitors. J Biomol Screen. 13, 591-608, doi:10.1177/1087057108321089 (2008).
33. Maréchal, E., Roy, S., & Lafanechère, L. Chemogenomics and Chemical Genetics: A User's Introduction for Biologists, Chemists and Informaticians. Springer (2011).
34. Gentzsch, J., et al. Hepatitis C virus complete life cycle screen for identification of small molecules with pro-or antiviral activity. Antiviral Res. 89, 136-148, doi:10.1016/j.antiviral.2010.12.005 S0166-3542(10)00824-7 [pii] (2011).
35. Caignard, G., et al. The V protein of Tioman virus is incapable of blocking type I interferon signaling in human cells. PLoS One. 8, e53881, doi:10.1371/journal.pone.0053881 PONE-D-12-16092 [pii] (2013).